Stryker Corporation Reports 9.4% Revenue Growth to $6.589 Billion in Q2 2026

Stryker Corporation reported a strong financial performance for the second quarter of 2026, with net sales reaching $6.589 billion, a 9.4% increase compared to $6.022 billion in the same period of 2025. For the first half of 2026, net sales totaled $12.609 billion, up 6.1% from $11.888 billion in the prior year. The company’s gross profit also saw a significant rise, amounting to $4.498 billion in the second quarter, compared to $3.841 billion in the previous year, resulting in a gross profit margin of 68.3%, up from 63.8%. Net earnings for the quarter were $1.276 billion, or $3.30 per diluted share, reflecting a 44.3% increase from $884 million, or $2.29 per diluted share, in the second quarter of 2025.

The company experienced notable changes in its operational structure, including the formation of a new business segment called Ortho Tech, which combines its orthopaedic instruments portfolio with enabling technologies. This reorganization aims to streamline operations and enhance customer experience. Stryker's MedSurg and Neurotechnology segment reported net sales of $3.625 billion for the second quarter, a 9.7% increase, while the Orthopaedics segment saw a 9.1% rise to $2.964 billion. The U.S. market contributed significantly to sales, with $4.959 billion in the second quarter, up from $4.554 billion in 2025.

In terms of operational metrics, Stryker's employee headcount remained stable, with 383.5 million shares of common stock outstanding as of June 30, 2026. The company reported a cash and cash equivalents balance of $3.391 billion, down from $4.011 billion at the end of 2025. The decrease in cash was attributed to cash used in investing activities, which totaled $824 million, primarily for property, plant, and equipment purchases, and cash used in financing activities, which amounted to $1.605 billion, driven by debt repayments and dividend payments.

Looking ahead, Stryker anticipates continued growth driven by its strategic focus on innovation and market expansion. The company aims to maintain its sales growth at the high end of the medical technology industry while prioritizing acquisitions, dividends, and share repurchases as part of its long-term capital allocation strategy. Despite challenges such as increased manufacturing costs and the impact of a recent cybersecurity incident, Stryker remains optimistic about its operational resilience and market position.